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Abstract
Ischemia and reperfusion (I/R) is an unavoidable condition during free flap transplan-
tation. Restoration of blood flow is usually associated with a profound inflammatory 
response. Cytokines and growth factors are the functional proteins which exert their 
specific influence on injury or repair during the healing period. Plasma concentrations 
of 18 cytokines and growth factor proteins (IL6, IL8, IP10, TNFα, MCP1, Fractalkine, 
GRO, bFGF, GMCSF, IFNg, MIP1a, VEGF, sCD40L, IL10, TGFα, IL1β, IL12P40, and 
TNFβ) have been analyzed with respect to I/R status during microsurgery tissue trans-
plantation in both, artery and vein, from patients by multiplexed immunoassay. Both 
technical feasibility and biostatistics data analysis approaches were thoroughly assessed. 
It has been found that, from all investigated proteins, the venous plasma levels of IL6 
significantly increased during the ischemia period and mostly sustained their high levels 
during reperfusion, while venous plasma levels of IL8 showed in general a significant 
increase in the ischemia period followed by a rapid decrease in the reperfusion period. 
In conclusion, these findings direct toward an active involvement of tissue-resting leuko-
cytes which may become therapeutic targets for concomitant medication in flap surgery 
to improve wound healing.
Keywords: IL6, IL8, multiplex analysis, microsurgery, free flap surgery, ischemia-reperfusion 
injury, reconstructive surgery, protein profiling
1. Introduction
Reconstructive microsurgery represents the most efficient approach to close large or complex 
tissue defects of the human body [1]. Microsurgical tissue transplantation, a standardized 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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technique in plastic and reconstructive surgery, unavoidably involves a time of ischemia in 
which the transplanted tissue can be harmed [2]. Also inevitable is the ischemia-reperfusion 
injury (I/R injury) [3, 4], limiting tissue survival in any microsurgical tissue transplantation 
[5]. Minutes after the onset of ischemia, reversible changes appear in tissues [6]. Irreversible 
injury develops after 20–40 min of sustained ischemia in muscle cells [7]. Intracellular con-
tents of necrotic cells initiate an inflammatory response and activate immune mechanisms. 
The main pathomechanisms of I/R injury involve the pathologic leukocyte-endothelium inter-
action [8, 9], production of reactive oxygen species [10, 11], and activation of the complement 
system [12] which can cause tissue damage [13] but also results in healing. The healing pro-
cess starts immediately after injury and consists of three phases: inflammation, proliferation, 
and tissue remodeling [14]. Knowledge about pathophysiology of I/R injury is mostly based 
on animal models [5, 15]. There are just a few reports focusing on free human muscle tissue 
transfer [2, 16], and up to now data about molecular processes that occur during free flap tis-
sue transfers of human skin or bone tissue are missing.
Since different tissues react in different ways to ischemia because of their specific metabo-
lisms, I/R injury was studied in subgroups: the microvascular transfer of muscle flaps, fas-
cio-cutaneous flaps, and osteo-cutaneous flaps. Assuming an involvement of tissue-resting 
leukocytes, intraoperative blood samples from 21 patients from artery and vein were collected 
at three different time points. To provide data on the protein concentration dynamics of cyto-
kines and growth factors (CGFs), a multiplex bead array assay was applied because of the 
assay’s high sensitivity, high throughput capability, and little sample consumption (only 25 μl 
plasma/serum) for analyzing numerous analytes in parallel [17, 18].
2. Results
2.1. Assay assessment, full analysis set, and per protocol set
A study with 21 patients encompassed 10 female and 11 male adults with various flap trans-
plants (Table 1). The osteo-cutaneous flaps (n = 9) were free fibula flaps for head and neck 
reconstructions in tumor diseases. Their ischemia times ranged from 90 to 220 min, in average 
133 min. The muscle flaps (n = 6) were mostly latissimus dorsi muscle flaps (n = 4), one gracilis 
muscle flap, and one serratus anterior muscle flap. All muscle flaps were needed for lower limb 
reconstruction. Their ischemia times varied from 60 to 120 min, in average 78 min. All fascio-
cutaneous flaps (n = 6) were radialis flaps. They were used to cover defects in the head and neck 
areas in tumor diseases. Their ischemia times ranged from 60 to 150 min, in average 78 min.
Mean weights of the transplanted flaps for the osteo-cutaneous group, the muscle group, and 
the cutaneous group were 92.67 ± 25.63, 249.25 ± 38.26, and 36.25 ± 39.92 g, respectively.
From each of the patients, three blood samples were taken during surgery. Artery (n = 21) 
represented the blood protein composition at a starting point, for comparison. At time point 
Vein 1, 18 samples, and at time point Vein 2, 19 samples were taken (see Appendix). Proteins 
whose concentrations were to be analyzed (i) were selected according to their main functions 
inflammation, angiogenesis, and apoptosis upon study of literature with respect to ischemia 
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and I/R injury and (ii) were matched with a commercially available bead-based immunoas-
say. From each of the patient samples, plasma concentrations of IL6, IL8, IP10, TNFα, MCP1, 
Fractalkine, GRO, bFGF, GMCSF, IFNg, MIP1a, VEGF, sCD40L, IL10, TGFα, IL1β, IL12P40, 
and TNFβ were simultaneously measured in duplicate. The raw data set of all 18 cytokines 
and growth factors of all samples encompassed 2088 data points which, after averaging and 
curation, were merged to the full analysis set (FAS) with 1044 protein concentration values 
(data not shown).
Free flap 
type
Patient ID Gender Age (y) Skin island 
(cm2)
Bone (cm) Transplant 
tissue
Weight (g) Ischemia 
(min)
Osteo-
cutaneous
101 Male 62 9 × 6 5.5 Fibula 80 90
102 Male 54 10 × 5 21 Fibula n.d.a 120
103 Male 55 n.d.a 20 Fibula n.d.a 220
104 Female 66 6.5 × 5 10.5 Fibula 110 95
105 Male 43 5 × 3 12 Fibula 72 150
106 Male 58 7 × 4 15 Fibula n.d.a 120
107 Female 57 6.5 × 5 8 Fibula 98 120
108 Female 67 6 × 4 12 Fibula 132 100
109 Female 70 7 × 5 13 Fibula 64 180
Muscle 201 Male 60 – – Latissimus 
dorsi
272 65
202 Female 66 – – Latissimus 
dorsi
198 60
203 Male 56 – – Latissimus 
dorsi
284 75
204 Male 40 – – Serratus 
anterior
n.d.a 80
205 Male 62 – – Gracilis n.d.a 70
206 Female 49 – – Latissimus 
dorsi
243 120
Fascio-
cutaneous
301 Female 26 5 × 4 – Radialis 14 80
302 Female 51 13 × 11 – Radialis 96 150
303 Female 64 6 × 5 – Radialis 20 80
304 Male 69 6 × 5 – Radialis 15 100
305 Female 79 9 × 5 – Radialis n.d.a 60
306 Female 37 14 × 12 – Radialis n.d.a 60
an.d.: not determined.
Table 1. Patient information and clinical parameters.
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Data from the FAS were inspected for completeness and categorized into three groups based 
on the detection rates. Group I contained those CGFs for which plasma protein concentrations 
could be determined in over 80% of all samples. Group II included those CGFs for which 
plasma protein concentrations could be determined in over 60% but less than 80% of all sam-
ples. Group III contained proteins whose concentrations were determined in less than 60% 
of all samples and sCD40L which did not pass the QC test. Group I proteins were IL8, IP10, 
MCP1, TNFα, GRO, IL6, Fractalkine, bFGF, and GMCSF. Group II contained four proteins: 
IFNg, MIP1α, VEGF, and IL10. Five proteins were placed in group III: TGFα, IL1β, IL12P40, 
TNFβ, and sCD40L (Table 2). Group III proteins were not subjected to further data analysis. 
Hence, the per protocol set (PPS) consisted of just group I and II proteins (13 proteins in total) 
and contained a total of 754 data points.
Some of the determined average plasma protein concentrations in the analyzed samples 
matched well with reported reference concentrations (e.g., TNFα and bFGF), whereas others 
did not. Differences between the “reference concentrations” and the concentrations deter-
mined in the here described study could be caused by (i) using different assays, (ii) different 
specimen (serum instead of plasma), (iii) different laboratory conditions, and (iv) different 
health conditions. Irrespective of such discrepancies, all the proteins of the PPS fell into the 
assay’s detection range and fulfilled the quality requirements, enabling further data analysis.
The intra-assay precision (CV%) of the determined protein concentrations were calculated 
for two assay plates of all group I and group II proteins to determine technical reproduc-
ibility (Table 2). The lowest CV% value of 5.97 was obtained for IP10, and the highest (16.99) 
for GMCSF. These values were slightly higher than those stated by the assay provider, most 
likely due to the fact that in the investigated study protein concentration levels varied from 
sample to sample because of the biological heterogeneities of the donors. Nevertheless, the 
CV% values were below 20 for all of the 13 cytokines and growth factors of the PPS, which 
is considered satisfactory [25–27]. Inter-patient CV% values between the averaged samples 
ranged from 352.63 for IL6 (in artery) to 40.76 for GRO (in artery).
2.2. Determination of data homogeneity
For testing whether or not Vein 1 samples of patients followed a trend with respect to ischemia 
time, linear regression analyses were performed to correlate ischemia time with mean con-
centrations of the PPS, i.e., group I and group II proteins (Figure 1). Both coefficients of deter-
mination (R2 values) and associated p values showed that there was no significant correlation 
between the two features for any of the tested proteins. This result indicated that sample values 
were rather randomly distributed with a fair homogenous distribution and only a few outliers.
In addition, hierarchical cluster analysis was conducted with group I proteins to characterize 
distribution of protein concentrations between patients. Plasma sampling time points (artery, 
Vein 1, and Vein 2) were analyzed independently from each other. The dendrograms and 
heat maps (Figure 2) revealed that in none of the sampling time points, the transplant types 
clustered together. Instead, within the blood sampling time points, all three transplant types 
seemed randomly distributed.
Issues in Flap Surgery6
PPS Protein name Uniprot acc. 
no.
Ref. value  
(pg/mL)3
Arteryc Vein 1d Vein 2e
Mean ± SD  
(pg/mL)
CV% Mean ± SD  
(pg/mL)
CV% Mean ± SD  
(pg/mL)
CV%
Group I IL6 P05231 22.80 ± 7.001 433.37 ± 1528.12 352.62 749.14 ± 916.28 122.31 692.80 ± 905.71 130.73
IL8 P10145 9.56 ± 0.401 123.55 ± 161.52 130.73 138.29 ± 117.54 85.00 119.45 ± 105.28 88.13
IP10 P02778 248.00 ± 96.502 759.29 ± 485.42 63.93 860.02 ± 645.74 75.08 815.83 ± 581.65 71.30
MCP1 P13500 173.20 ± 15.401 2160.00 ± 2626.43 121.59 2654.86 ± 2462.78 92.76 2520.15 ± 2208 87.61
TNFα P01375 34.22 ± 11.461 18.78 ± 10.70 56.98 20.50 ± 10.83 52.82 18.67 ± 9.49 50.83
Fractalkine P78423 423.00 ± 25.003 137.17 ± 110.49 80.55 126.62 ± 119.15 94.10 151.21 ± 124.79 82.53
GRO P09341 212.20 ± 21.804 1780.41 ± 725.66 40.76 2301.17 ± 1287.76 55.96 2423.88 ± 1253.26 51.70
bFGF P09038 76.60 ± 17.532 90.76 ± 82.81 91.25 117.07 ± 73.80 63.04 87.27 ± 56.81 65.10
GMCSF P04141 2.43 ± 0.085 8.59 ± 6.33 73.70 10.80 ± 10.81 100.11 8.47 ± 6.50 76.73
Group II IFNg P01579 18.30 ± 9.152 42.18 ± 92.71 219.80 28.70 ± 39.87 138.89 51.41 ± 100.51 195.51
MIP1a P10147 88.10 ± 14.311 22.14 ± 33.49 151.27 14.62 ± 16.86 115.34 14.22 ± 16.51 116.13
VEGF P15692 32.20 ± 21.806 283.19 ± 356.83 126.00 310.49 ± 385.78 124.25 305.3 ± 349.13 114.36
IL10 P22301 7.63 ± 5.952 66.79 ± 129.79 194.31 63.28 ± 162.14 256.23 79.89 ± 170.61 213.54
aTotal number of samples: N = 58 from 21 transplantation patients.
bReference concentrations from healthy donors:
1Mean ± SE; multiplex bead assay: Yurkovetsky et al. [19].
2Median ± quartile difference; multiplex bead assay: Geyer et al. [20].
3Mean ± SE; EIA: Damas et al. [21].
4Mean ± SD; multiplex bead assay: Hang et al. [22].
5Mean ± SE; ELISA: Lee et al. [23].
6Mean ± SD; ELISA: Larsson et al. [24].
cArtery blood was collected before anastomosis (N = 21).
dVein 1 blood was collected directly after anastomosis (N = 18).
eVein 2 blood was collected 2 min after Vein 1 blood (N = 19).
Table 2. Averaged plasma concentrations of the per protocol set cytokines/growth factors in artery and vein samplesa.
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GMCSF, TNFα, Fractalkine, bFGF, and IL8 were found in low concentrations (below 500 pg/
mL; colored black in Figure 3), whereas IP10 was found with intermediate concentration (500 
pg/mL < protein concentration < 1000 pg/mL; colored dark grey) in all three sampling time 
points (artery, Vein 1, and Vein 2). MCP1 and GRO were present in highest concentrations 
(above 1000 pg/mL; colored bright grey) in most samples of all three sampling time points. 
Interestingly, IL6 was found to change in concentration from low in artery to intermediate in 
both, Vein 1 and Vein 2 samples, and prompted to analyze protein concentration differences 
between sampling time points.
2.3. Analysis of individual protein concentration dynamics
To investigate expression differences between the sampling time points for each patient, 
ratios between the respective protein concentrations were calculated. Quotient I (artery/
artery), quotient II (Vein 1/artery), and quotient III (Vein 2/artery) showed individual val-
ues for all three time points in a normalized fashion. Combining these quotients, values 
with straight lines visualized “up” and “down” and/or “no” changes, respectively. From all 
investigated protein concentrations, a “dynamic” expression was observed for IL6 and IL8 
in individual patients.
Figure 1. Linear regression plots for group I proteins between ischemia time and protein concentrations of all patients’ 
Vein 1 samples. Trend lines are shown. R2 values are given.
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Figure 2. Hierarchical clustering analysis of protein concentrations from artery (A), Vein 1 (B), and Vein 2 (C) plasma 
samples of flap transplant patients. Proteins are indicated on the left. Patient IDs (Table 1) are given between the 
dendrogram and the heat map illustration. Grey scales indicate protein concentration: black—low, dark grey—medium, 
bright grey—high.
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Nearly all line graphs for IL8 in all patients showed progression lines that were quite similar 
to each other (Figure 3A). The dominant protein concentration change profile of IL8 followed 
a rapid “up-down” trend. A few patients in the IL8 group (104, 107, 201, 302, and 305) rep-
resented a “slow dynamic,” i.e., an “up-no” trend. Interestingly, line graphs for IL6 of most 
Figure 3. Line graphs of concentration ratios from 21 patients (58 plasma samples) for IL8 (A) and IL6 (B). Individual 
ratios were calculated from protein concentrations: I: artery/artery, II: Vein 1/artery, and III: Vein 2/artery. Patient IDs 
(Table 1) and respective symbols are shown at the right.
Issues in Flap Surgery10
patients followed a related progression (Figure 3B) as well. The dominant protein profile for 
IL6 followed an “up-no” trend. Noteworthy, with a few patients (104, 106, 108, 206, and 304) 
from the IL6 group, a “fast dynamics” of protein concentration changes (“up-down” trend) 
was observed.
2.4. Subgroup analysis of different free flap tissue groups
Subgroup analysis of protein profiles with respect to different transplant types was per-
formed to check whether the trend of the general protein concentration profiles of either IL6 
or IL8 was found consistently in the clinical subgroups. In each of the three transplant groups 
(Figure 4), the “up-no” trend of IL6 was dominant (10 cases), followed by the “up-down” 
trend (5 cases).
Notably, the PPS data in the osteo-cutaneous group showed very large differences of IL6 con-
centrations between the pre-ischemia time point (artery) and the second post-ischemia time 
point (Vein 2) in patients 103, 105, and 109 (“up-no” trend). In patient 103, the difference was 
2398.4 pg/mL; in patient 105, it was 3320.68 pg/mL; and in patient 109, 1549.19 pg/mL. These 
three patients experienced the longest ischemia times during operation (Table 1). Patient 109 
developed a venous thrombosis after venous anastomosis, so a revision of the anastomosis 
with thrombectomy and an interposition of a vein graft became necessary.
Of note, in the skin flap group, the pre-ischemia value (artery) of IL6 was higher in patients 
with clinical conspicuities compared to the other patients. In patient 305, the pre-ischemia 
IL6 concentration was 144.98 pg/mL, and in patient 302, it was 147.34 pg/mL. In the other 
patients of this group, the pre-ischemia IL6 concentrations were much lower and the mean 
was 52.15 pg/mL. Patient 305 developed an intraoperative thrombosis of the artery after 
venous anastomosis. In patient 302, ischemia time was the longest in the whole group with 
150 min.
In case of IL8, the “up-down” trend was dominant (five cases) in both, the osteo-cutaneous 
group (Figure 5A) and the cutaneous group (Figure 5C), followed by the “up-no” trend (four 
cases). Only the muscle group seemed to behave different (Figure 5B). Here, no dominant 
trend could be defined, but “up-down” cases were present.
Again, when looking at the PPS data also in the muscle group, the two patients (patients 
202 and 203) with clinical conspicuities were standing out by looking at the concentrations 
of IL6 and additionally of IL8. In these patients, the pre-ischemia values (artery) of both, 
IL6 and IL8, were significantly higher than those of the other patients. The IL6 concentra-
tion of patient 202 was 30.47 pg/mL and that of patient 203 was 7064.18 pg/mL. Although 
both values were very different, they were much higher than the mean concentration of the 
other patients which was 12.81 pg/mL. Similarly, the IL8 concentration of patient 202 was 
530.33 pg/mL and that of patient 203 was 477.09 pg/mL. These concentrations were again 
much higher than the mean (202.16 pg/mL) of all other patients in this group. Patient 202 
suffered from partial flap necrosis, whereas patient 203 developed an intraoperative venous 
thrombosis after venous anastomosis, so a revision of the anastomosis with thrombectomy 
was necessary.
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In sum, subgroup analysis confirmed that the dynamics of protein concentration differences of 
IL6 and IL8 correlated with I/R and seemed capable to characterize I/R-related processes on a 
molecular level for both the patients that showed clinical conspicuities or complications and those 
that did not. These concentration differences point toward a (transient) activation of leukocytes.
Figure 4. Line graphs of concentration ratios for IL6 from osteo-cutaneous flaps (A), muscle flaps (B), and skin flaps (C). 
Individual ratios were calculated from protein concentrations: I: artery/artery, II: Vein 1/artery, and III: Vein 2/artery. 
Patient IDs (Table 1) and respective symbols are shown at the right.
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2.5. Conclusion
The dynamic nature of the circulating blood system and its constituents reflects diverse physi-
ological or pathological states and, together with the ease with which blood can be sampled, 
Figure 5. Line graphs of concentration ratios for IL8 from osteo-cutaneous flaps (A), muscle flaps (B), and skin flaps (C). 
Individual ratios were calculated from protein concentrations: I: artery/artery, II: Vein 1/artery, and III: Vein 2/artery. 
Patient IDs (Table 1) and respective symbols are shown at the right.
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makes it a logical choice for biomarker investigations [28]. Based on the inspection of the 
individual protein profiles of 18 cytokines and growth factors in the investigated study cohort 
(Table 3), IL8 and IL6 showed dynamic changes within the measured time frame.
IL6 together with TNFα and IL1β belongs to the so-called pro-inflammatory cytokines. IL6 
is supposed to activate the coagulation system in experimental models, due to cross-links 
Classificationa Cytokine/growth 
factor
Protein family Receptorb,c Cytokine/growth 
factor target cell 
typesc,d
Dynamic changee IL8 Cytokine/chemokine CXCR1, E482 Neutrophils, 
basophils, CD8 
T cells, epithelial 
and endothelial 
cells
IL6 Cytokine/interleukin CD126, CD130 T cells, B cells
No dynamic changef MCP1 Cytokine/chemokine CCR2 T cell monocytes, 
NK cells, B cells, 
endothelial cells
bFGF Growth factor (fibroblast) FGFR Epithelial cells
GRO Cytokine/chemokine CXCR2 Neutrophils, 
fibroblasts, 
melanoma cells
Fractalkine Cytokine/chemokine CX3CR1 Activated T cells, 
neutrophils, NK 
cells
GMCSF Cytokine/interleukin CD116, βc Bone marrow 
progenitors
IP 10 Cytokine/chemokine CXCR3A, CXCR3B Activated T cells, 
NK cells, B cells, 
endothelial cells
TNF α Cytokine (TNF) CD120a, CD120b T cells, B cells, 
endothelial cells
MIP 1α Cytokine/chemokine CCR1, CCR5 Immune cells, 
smooth muscle 
cells, endothelial 
cells
IL10 Cytokine/interleukin IL-10Rα, IL-10Rβc Macrophages, T 
cells
VEGF Growth factor (vascular 
endothelial)
VEGFR Vascular 
endothelial cells, 
hematopoietic 
stem cells, 
megakaryocytes
IFNγ Cytokine/interleukin CD119, IFNGR2 Monocytes, 
endothelial cells, 
macrophages
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between inflammation and coagulation [32, 33]. Activated coagulation can result in micro-
vascular thrombosis that possibly increases I/R injury [34]. Myocardial ischemia studies 
assume that changes in coagulation affect the resolution of ischemia during reperfusion due 
to changes in no-flow regions [35, 36]. In mice, IL6 deficiency reduced myocardial infarct size 
at 3 h reperfusion from which it was concluded that IL6 contributed to the development of 
infarct size in the early phase of reperfusion [37]. These results correspond to significantly 
elevated concentrations of IL6 in the venous blood samples of patients that experienced long 
ischemia periods.
IL8 is a prototypical member of the CXC chemokine family. Chemokines control innate 
immune cell trafficking between the bone marrow, blood, and peripheral tissues dur-
ing inflammation. IL8 is a potent chemoattractant for neutrophils in vitro [38]. It has been 
reported to be a chemoattractant for a subset of T-lymphocytes [39]. IL8 is also called neutro-
phil-activating protein 1 (NAP-1) because it stimulates release of neutrophil granules. Like 
many other chemoattractants, IL8 induces re-arrangement of the cytoskeleton, changes in 
intracellular Ca2+ levels, activation of integrins, exocytosis of granule proteins, and respira-
tory burst [40]. IL8 concentration dynamics results in the here described study are consistent 
with published data, demonstrating the potential of IL8 as a marker protein of I/R injury in 
transplantation surgery. Interestingly, in cases of clinical conspicuities or complications, IL6 
and IL8 react differently as compared to inconspicuous cases.
The activated forms of both macrophages and keratinocytes can release a number of inflam-
matory and cytotoxic active molecules that play essential roles in wound repair and/or tissue 
damage [41–43]. Macrophages, by secreting IL6, were suggested to interact with keratinocytes 
Classificationa Cytokine/growth 
factor
Protein family Receptorb,c Cytokine/growth 
factor target cell 
typesc,d
Undetermined sCD40L Cytokine (TNF) CD40 Dendritic cells, B 
cells, macrophages
TGF α Growth factor (EGF-like 
domain)
EGFR Epithelial cells
IL1β Cytokine/interleukin CD121a, CD121b T cells, 
macrophages
IL12P40 Cytokine/interleukin IL-12β1c + IL-12β2 NK cells, T cells
TNFβ Cytokine (TNF) CD120a, CD120b T cells, 
macrophages
aComparisons of means of protein concentrations between sampling time points artery, Vein 1, and Vein 2.
bBaggiolini et al. [29].
cJaneway et al. [30].
dHuret et al. [31].
eMeans are different between sampling time points artery, Vein 1, and Vein 2.
fMeans are similar between sampling time points artery, Vein 1, and Vein 2.
Table 3. Classification of proteins according to their averaged plasma concentrations.
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which are associated with epithelialization [44]. IL8 has a profound effect on the migration 
of keratinocytes which is again critical to wound epithelialization [45]. In vitro experiments 
on the effect of recombinant human IL8 on keratinocyte proliferation revealed a rise in cell 
numbers, whereas in vivo topically applied IL8 on human skin grafts in a chimeric mouse 
model enhanced re-epithelialization due to elevated numbers of mitotic keratinocytes [46]. 
The dynamic occurrence of chemokines IL8, GROα, MCP-1, IP-10, and Mig in the different 
phases of wound healing was described in a skin repair model in adult humans [47].
3. Outlook
The concept of targeting receptor cells that bind to IL6 or IL8 might become of importance for 
clinical interventions with the aim to accelerate wound healing as well as to attenuate fibro-
sis in response to individually determined cytokine/growth factor concentrations (Figure 6). 
Sequential function of endogenous IL8 and IL6 in all phases of human wound healing suggests 
to administering appropriate medication [48] in case of overexpression.
For instance, the anti-interleukin-6 receptor monoclonal antibody, tocilizumab, which was 
approved for the treatment of inflammatory diseases [49], might be tested in an off-label clini-
cal study for its effect in modulating immune responses during free flap healing. A similar 
therapeutic concept may make use of HuMab 10FB, a fully human mAb against IL8, which 
Figure 6. Implications of leucocytes (macrophages) in wound healing processes and clinical management without (left) 
and with (right) neutralizing antibody-based medication. Overproduced cytotoxic mediators or their receptors may be 
targeted. Pro-inflammatory mediators and enzymes may be clinically managed, whereas anti-inflammatory mediators 
would not be affected.
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binds a discontinuous epitope on IL8 overlapping the receptor binding site, and it is capable 
to interrupt IL8 activity in vivo [50]. Both therapeutic antibodies would neutralize increased 
levels of interleukins and directly interfere in leukocyte signaling with potentially positive 
effects on tissue and wound healing processes.
These results indicate the sequential function of endogenous MCSF [51], IL8, and IL6 in 
wound healing which in case of overexpression may be clinically managed by administering 
appropriate medication, i.e., management of an individuals’ systemic inflammatory status to 
reduce or even prevent conspicuities and complications during perioperative and postopera-
tive periods. Concomitant medication may become an important if not indispensable part of 
state-of-the-art flap surgery in the future.
4. Appendix
4.1. Clinical specimen collection
Presented and discussed data are from a study that was approved by the Institutional Review 
Board of the University Hospital Zurich, Switzerland (StV 8-2009). Written informed con-
sent was obtained from all participating patients. Three groups of free flap transfers were 
defined: (i) muscle flaps, e.g., gracilis flap, latissimus dorsi flap, serratus anterior flap, (ii) 
fascio-cutaneous flaps, e.g., radialis flap, anterolateral thigh flap, and (iii) osteo-cutaneous 
flaps, i.e., fibula flaps. Clinical measurements include the ischemia time, flap weight, length 
of bone (in fibula flaps), and the dimension of the skin island. Patients qualified for the study 
had to be with normal weight (BMI 20–25), non-diabetics, in no manifest infection situation, 
and of good health with no essential diseases besides the main diagnosis (Table 1). Blood 
samples were taken intraoperatively prior to arterial anastomosis from the arterial inflow 
and after arterial anastomosis from the venous flap outflow. Vein 1 samples were taken 
directly after anastomosis and Vein 2 samples 2 min after collecting Vein 1 samples in 1.5 
mL portions using S-Monovette® Lithium Heparin syringes (Monovette®, Sarstedt, Germany). 
Blood samples were immediately subjected to sedimentation of blood cells by centrifuga-
tion at 2000 g at room temperature for 15 min. Plasma was aspirated and sterile-filtered (0.2 μm 
pore size) [52]. Five samples had to be excluded from the study because of too less material 
after  centrifugation and sterile filtration: patient 109 (Vein 1), patient 203 (Vein 2), patient 204 
(Vein 1), and patient 306 (Vein 1 and Vein 2). In total, 58 plasma samples had been collected. 
Aliquots of 100 μL per portion were stored at –80°C prior to further analysis.
4.2. Multiplexed bead-based immunoassay
The Human Cytokine/Chemokine Magnetic Bead Panel from Milliplex® (Map kit HCYTOMAG-
60K, Billerica, MA, USA) contained antibodies against 18 proteins that were delivered immo-
bilized onto color-coded beads. All kit reagents were brought to 25°C. Then, the two quality 
control samples were reconstituted with 250 μL deionized water, each. Serum matrix was recon-
stituted with 1.0 mL deionized water. The human cytokine standard mixture was reconstituted 
with 250 μL deionized water to give a 10,000 pg/mL concentration for each of the standards. This 
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solution was serially diluted by a factor of 5 and yielded in diluted human cytokine standards 
with the following concentrations: 10,000, 2000, 400, 80, 16, and 3.2 pg/mL. Next, each anti-
body-bead containing vial was sonicated for 30 s and then vortexed for 1 min. Sixty microli-
ters of antibody-bead slurry from each of the 18 vials was added to the mixing bottle, and 1.92 
mL “bead diluent” was added to achieve a final volume of 3.0 mL. Two 96-well plates were 
pre-wetted with 200 μL wash buffer, each. After sealing, the plates were fixed on the shaker 
(Heidolph® Promax 2020, Schwabach, Germany) and gently agitated for 10 min at room tem-
perature. The wash buffer was decanted, and the residual amount was removed by inverting 
the plates and gently tapping onto absorbent towels for several times. Twenty-five microliters, 
each, of all six diluted human cytokine standards and the two quality control samples were 
added into their dedicated wells. Twenty-five microliters, each, of assay buffer were added 
to two “background” wells and to the wells that were dedicated to patient samples. Second, 
25 μL of serum matrix was added into each of the diluted human cytokine standard wells, 
the background wells, and the quality control sample wells. Twenty-five microliters of each 
patient plasma was added into one of the patient sample wells. Twenty-five microliters, each, 
of antibody-bead slurry from the mixing bottle was added to all the wells. Afterwards, plates 
were sealed and incubated in the dark for 18 h at 4°C on the plate shaker. Solvents from 
each well were removed, avoiding loss of beads, and beads were washed twice with wash 
buffer (200 μL, for each well, 1 min incubation). After removal of wash buffer, 25 μL, each, 
of detection antibody solution was added to all wells. After 1 h incubation at 25°C, 25 μL 
of phycoerythrin-loaded streptavidin containing solution was added to all wells. The plates 
were sealed again, covered with aluminum foil, and then fixed on the plate shaker for 30 min 
at 25°C. Subsequently, beads were washed twice with wash buffer (200 μL, for each well, 1 
min incubation). After removal of wash buffer, 150 μL of sheath fluid (Bio-Rad Laboratories, 
Hercules, CA, USA) was added to all wells and beads were resuspended on the plate shaker 
for 5 min. Plates were placed into the Bio-Plex suspension array 200 System (Bio-Rad 
Laboratories, Hercules, CA, USA), which had been calibrated with Bio-Plex® 200 calibration 
kit and validated with Bio-Plex® validation kit 4.0 (Bio-Rad Laboratories, Hercules, CA, USA). 
Measurement settings were as follows: data acquisition, 50 beads per region; sample size, 
100 μL; and doublet discriminator gate, 5000–25,000 (low photomultiplier tube). The Bio-Plex 
suspension array 200 reader system contains a red laser for identification of the bead which 
is analyzed and a green laser for quantification of fluorescence intensity of phycoerythrin-
loaded streptavidin. All standards, controls, background, and plasma samples were prepared 
in duplicate and measured once. From the 2088 independent measurements, the Bio-Plex® 
manager 6.1 software (Bio-Rad Laboratories, Hercules, CA, USA) calculated median fluo-
rescence intensity (MFI) and standard deviations of each duplicate recording. Fluorescence 
values of human cytokine standards were plotted as standard curves which were used for 
determining plasma concentrations (pg/mL) based on their fluorescence intensities of all pro-
teins and all time points. In total, 1044 data points (raw data set) were stored as Excel files.
4.3. Full analysis set and per protocol set
Data from the raw data set were inspected for completeness and categorized into three groups 
based on the detection rates. Group I contained those cytokines and growth factors (CGFs) for 
which plasma protein concentrations could be determined in over 80% of all samples. Group 
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II included those CGFs for which plasma protein concentrations could be determined in over 
60% but less than 80% of all samples. Group III contained proteins whose concentrations were 
determined in less than 60% of all samples and sCD40L which did not pass the QC test. In 
both, group I and group II proteins, the missing values were imputed using the lower limit 
of quantitation (LLOQ) except for MCP1 for which upper limit of quantitation (ULOQ) was 
imputed. After imputing, the “full analysis set (FAS)” contained a total of 1044 curated data 
points (data not shown). The “per protocol set (PPS)” was generated out of the “full analysis 
set (FAS)” by including only group I and group II CGFs, resulting in 754 data points.
4.4. Biostatistical analysis
Statistical analyses were performed using the PPS with the IBM statistics software SPSS (ver-
sion 20.0, SPSS Inc., Chicago, USA). Linear fit analysis between ischemia time and protein 
concentration was performed using the Origin statistics software (version. 8.1 G; OriginLab 
Corporation, Northampton, MA, USA). Linear regression was performed to calculate R2 
values, and ANOVA tests were performed to calculate p values to estimate whether protein 
concentration was related to the ischemia time [53]. Hierarchical cluster analysis and dendro-
gram presentation were performed on the Knowledge Discovery Environment (KDE) plat-
form (InforSense Ltd., London, UK). Parameter settings were single linkage and Euclidean 
distance. CV% for each analyte was calculated as the ratio of the standard deviation to the 
plasma mean concentration [25, 26].
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